Stockreport

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics, Inc.  (KLRS) 
PDF Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enroll [Read more]